PARP3
ENSG00000041880
Target class
Enzyme
Chromosome
3
Approved drugs
3
Clinical candidates (approved and in development)
5
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- No
- Target name
- PARP3
- Gene name
- Poly(ADP-ribose) polymerase family member 3
- Gene symbol
- PARP3
- Previous gene symbols
- ADPRTL3
- Protein name
- Protein mono-ADP-ribosyltransferase PARP3 (EC 2.4.2.-) (ADP-ribosyltransferase diphtheria toxin-like 3) (ARTD3) (DNA ADP-ribosyltransferase PARP3) (EC 2.4.2.-) (IRT1) (NAD(+) ADP-ribosyltransferase 3) (ADPRT-3) (Poly [ADP-ribose] polymerase 3) (PARP-3) (hPARP-3) (Poly[ADP-ribose] synthase 3) (pADPRT-3)
- ADPRT3
- IRT1
- hPARP-3
- pADPRT-3
- ARTD3
- Gene biotype
- Protein coding
- Gene family
- Poly(ADP-ribose) polymerases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 50.46
- Tissue specificity (Gini)
- 0.248
- Tissue specificity (tau)
- 0.589
- KEGG gene identifiers
- hsa:10039
- Protein interaction confidence
- 0.807357
- Protein interaction partners
- 14
- End position
- 51948871
- Start position
- 51942252
- Chromosome
- 3
- Strand
- Forward
- Nucleus . Chromosome . Cytoplasm, cytoskeleton, microtubule organizing center, centrosome . Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole . Note=Almost exclusively localized in the nucleus and appears in numerous small foci and a small number of larger foci whereas a centrosomal location has not been detected (PubMed:16924674). In response to DNA damage, localizes to sites of double-strand break (PubMed:21270334, PubMed:28447610). Also localizes to single-strand breaks (PubMed:27530147). Preferentially localized to the daughter centriole (PubMed:10329013). .
- Nuclear bodies
- Nucleoplasm
- PubMed 16924674
- PubMed 21270334
- PubMed 27530147
- PubMed 28447610
- PubMed 10329013
- Tissue specificity (tau)
- 0.589292
- Expression inequality (Gini)
- 0.248047
Expression in transcripts per million
- Adrenal Gland
- 50.46
- Thyroid
- 47.18
- Cells - Cultured fibroblasts
- 36.4
- Bladder
- 33.32
- Colon - Sigmoid
- 32.25
Expression in transcripts per million
- Adrenal Gland50.46
- Thyroid47.18
- Cells - Cultured fibroblasts36.4
- Bladder33.32
- Colon - Sigmoid32.25
- Nerve - Tibial32.16
- Small Intestine - Terminal Ileum31.47
- Cells - EBV-transformed lymphocytes30.99
- Breast - Mammary Tissue30.79
- Prostate30.37
- Esophagus - Muscularis30.07
- Spleen27.34
- Lung26.88
- Artery - Aorta26.48
- Adipose - Subcutaneous26.32
- Uterus26.17
- Esophagus - Gastroesophageal Junction25.71
- Adipose - Visceral (Omentum)25.26
- Artery - Coronary24.82
- Colon - Transverse24.8
- Cervix - Endocervix24.13
- Fallopian Tube23.87
- Kidney - Cortex23.8
- Vagina23
- Cervix - Ectocervix22.17
And 29 more, listed on the interactive page.
- GO:0000723
- GO:0006302
- GO:0006303
- GO:0030592
- GO:0032211
- GO:0060236
- GO:0070212
- GO:0070213
- GO:1990166
- GO:2001034
- GO:0005634
- GO:0005654
- GO:0005694
- GO:0016604
- GO:0035861
- GO:0003824
- GO:0003950
- GO:0005515
- GO:0140294
- GO:0140804
- GO:0140806
- GO:0140807
- GO:1990404
Related records
Trials (584)
- 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
- 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
- A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer
- A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer
- A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer
- A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
- A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer
- A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer
- A Dye for the Detection of Cancer of the Tongue and Mouth
- A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors
- A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors
- A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
- A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
- A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
- A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
- A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
- A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors
- A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer
Drugs (5)
- E-7016 PARP 1, 2 and 3 inhibitor
- Olaparib PARP 1, 2 and 3 inhibitor
- Rucaparib PARP 1, 2 and 3 inhibitor
- Rucaparib camsylate PARP 1, 2 and 3 inhibitor
- Veliparib PARP 1, 2 and 3 inhibitor